Verastem Stock Surges Over 50% on Positive Pancreatic Cancer Drug Data
TL;DR Summary
Verastem (VSTM) stock plummeted by 62% following the release of clinical trial data for its metastatic pancreatic cancer treatment, which revealed serious adverse events in 12 patients, including 11 with grade ≥3 events. Despite initial positive results, the safety concerns led to heavy trading and a significant drop in stock value.
- Why Is Verastem (VSTM) Stock Down 62% Today? InvestorPlace
- Verastem Oncology Announces Positive Initial Interim Safety and Efficacy Results from RAMP 205 Trial Evaluating Avutometinib Plus Defactinib in Combination with Gemcitabine and Nab-paclitaxel in First-Line Metastatic Pancreatic Cancer Yahoo Finance
- Verastem Oncology Announces the Initiation of a Rolling Submission of NDA to FDA Seeking Accelerated Approval of Avutometinib and Defactinib Combination for the Treatment of Adult Patients with Recurrent KRAS Mutant Low-Grade Serous Ovarian Cance Business Wire
- Verastem stock rallies on positive data for pancreatic cancer drug combo Seeking Alpha
- Verastem shares surge more than 50% after pancreatic-cancer treatment study data MarketWatch
Reading Insights
Total Reads
0
Unique Readers
2
Time Saved
2 min
vs 3 min read
Condensed
88%
435 → 51 words
Want the full story? Read the original article
Read on InvestorPlace